Astria Therapeutics, Inc. (ATXS)
NASDAQ: ATXS · Real-Time Price · USD
12.51
+0.08 (0.64%)
At close: Nov 7, 2025, 4:00 PM EST
12.51
0.00 (0.00%)
After-hours: Nov 7, 2025, 4:00 PM EST
Astria Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
78
Market Cap
707.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ATXS News
- 1 day ago - Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart - Business Wire
- 7 days ago - Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - Business Wire
- 21 days ago - Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS - Business Wire
- 24 days ago - BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate' - Benzinga
- 24 days ago - BioCryst to buy Astria Therapeutics in $700 million deal - Reuters
- 24 days ago - BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile - Business Wire
- 4 weeks ago - Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting - Business Wire
- 4 weeks ago - Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema - Business Wire